Payment overview · 2025
General Payments
$16.61
1 reported records · 1 companies
Healthcare provider profile · identity verified
Brent J Layton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GLOBE, AZ · NPI 1861454530
Verified facts
What the public records show
CMS Open Payments records show Brent J Layton, MD received $16.61 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.61 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.61 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 431 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 103 |
| Losartan Potassium | Losartan Potassium | 365 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 85 |
| Furosemide | Furosemide | 289 | 73 |
| Lisinopril | Lisinopril | 287 | 80 |
| Gabapentin | Gabapentin | 233 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 57 |
| Warfarin Sodium | Warfarin Sodium | 200 | suppressed |
| Eliquis | Apixaban | 198 | 25 |
| Finasteride | Finasteride | 185 | 41 |
| Potassium Chloride | Potassium Chloride | 174 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 35 |
| Sertraline Hcl | Sertraline Hcl | 151 | 33 |
| Carvedilol | Carvedilol | 146 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 33 |
| Allopurinol | Allopurinol | 125 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 33 |
| Metformin Hcl | Metformin Hcl | 108 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 108 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 32 |
| Metformin Hcl Er | Metformin Hcl | 102 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 19 |
| Ezetimibe | Ezetimibe | 99 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 31 |
| Glipizide Er | Glipizide | 96 | 27 |
| Donepezil Hcl | Donepezil Hcl | 90 | 24 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 15 |
| Methylprednisolone | Methylprednisolone | 81 | 57 |
| Memantine Hcl | Memantine Hcl | 75 | 12 |
| Tramadol Hcl | Tramadol Hcl | 74 | 21 |
| Trazodone Hcl | Trazodone Hcl | 73 | 23 |
| Spironolactone | Spironolactone | 72 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 26 |
| Azithromycin | Azithromycin | 66 | 54 |
| Prednisone | Prednisone | 66 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 18 |
| Alprazolam | Alprazolam | 59 | suppressed |
| Omeprazole | Omeprazole | 58 | 18 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Xarelto | Rivaroxaban | 56 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 13 |
| Baclofen | Baclofen | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 13 |
| Olanzapine | Olanzapine | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 46 |
| Ozempic | Semaglutide | 50 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 49 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Atenolol | Atenolol | 43 | 12 |
| Levofloxacin | Levofloxacin | 43 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 30 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Pregabalin | Pregabalin | 41 | 21 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | 13 |
| Nystatin | Nystatin | 40 | 16 |
| Mirtazapine | Mirtazapine | 39 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 16 |
| Cephalexin | Cephalexin | 38 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | 11 |
| Glipizide | Glipizide | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 13 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Topiramate Er | Topiramate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Clonidine | Clonidine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.61 · 1 records | Novo Nordisk Inc | Ozempic | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error